PHAT
Phathom Pharmaceuticals, Inc.
$9.18
+0.24
(+2.68%)
Mkt Cap
742.67M
Volume
894,426
52W Range
8.21-18.31
Sector
Healthcare
Beta
0.50
EPS (TTM)
-1.28 USD
P/E Ratio
-5.48
Revenue (TTM)
239.66M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 175.11M | 55.25M | 682,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (221.25M) | (334.33M) | (201.59M) | (197.72M) | (143.88M) | (129.07M) | (209.74M) | (1.29M) |
| EPS | -3.03 | -5.29 | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Free Cash Flow | (166.78M) | (266.90M) | (139.21M) | (147.57M) | (148.78M) | (70.73M) | (61.76M) | (1.02M) |
| FCF / Share | -2.29 | -4.22 | -2.71 | -3.77 | -4.02 | -2.13 | -2.50 | -0.12 |
| Operating CF | (166.78M) | (266.77M) | (137.58M) | (146.53M) | (148.46M) | (69.69M) | (36.51M) | (1.02M) |
| Total Assets | 259.15M | 378.32M | 413.84M | 164.81M | 189.43M | 295.11M | 257.18M | 902,000 |
| Total Debt | 211.80M | 201.91M | 139.03M | 97.07M | 91.34M | 49.02M | 23.57M | 1.95M |
| Cash & Equiv | 129.97M | 297.26M | 381.39M | 155.38M | 183.26M | 287.50M | 243.76M | 879,000 |
| Book Value | (438.17M) | (253.58M) | (72.76M) | (74.81M) | 72.16M | 194.27M | 227.96M | (1.29M) |
| Return on Equity | N/A | N/A | N/A | N/A | -1.99 | -0.66 | -0.92 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 74.27M | 58.30M | 57.58M | 49.50M | 39.50M | 28.52M | 29.66M | 16.35M | 7.32M | 1.91M | 682,000 | 0 |
| Net Income | (17.58M) | (30.37M) | (21.15M) | (29.97M) | (75.81M) | (94.32M) | (74.45M) | (85.58M) | (91.45M) | (82.85M) | (79.57M) | (43.24M) |
| EPS | -0.21 | -0.37 | -0.29 | -0.41 | -1.05 | -1.31 | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 | -0.76 |
| Free Cash Flow | (1.97M) | (15.71M) | (4.89M) | (14.14M) | (62.73M) | (84.95M) | (63.46M) | (63.49M) | (70.77M) | (69.06M) | (44.27M) | (32.85M) |
| FCF / Share | -0.02 | -0.19 | -0.07 | -0.19 | -0.87 | -1.18 | -0.89 | -0.98 | -1.21 | -1.18 | -0.77 | -0.58 |
| Operating CF | (1.93M) | (15.65M) | (5.00M) | (14.12M) | (62.73M) | (84.93M) | (63.46M) | (63.57M) | (70.72M) | (69.02M) | (43.80M) | (31.91M) |
| Total Assets | 327.07M | 305.12M | 259.15M | 240.29M | 250.22M | 294.21M | 378.32M | 387.04M | 319.38M | 356.50M | 413.84M | 236.99M |
| Total Debt | 167.11M | 166.30M | 211.80M | 209.81M | 205.97M | 203.56M | 201.91M | 176.41M | 175.28M | 150.04M | 139.03M | 100.61M |
| Cash & Equiv | 182.48M | 180.90M | 129.97M | 135.16M | 149.57M | 212.31M | 297.26M | 334.68M | 276.24M | 322.23M | 381.39M | 213.68M |
| Book Value | (344.27M) | (336.95M) | (438.17M) | (422.53M) | (405.83M) | (338.38M) | (253.58M) | (187.11M) | (233.83M) | (148.50M) | (72.76M) | (17.77M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PHAT News
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals Q2 Earnings Call Highlights
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)